What is the global market size of Myocardial Infarction (MI) Therapeutics Market?

Myocardial Infarction (MI) Therapeutics Market was valued to be US$ 1.91 billion in 2019, and it is expected to reach US$ 2.65 billion by 2031 at a CAGR of 4.82% over the forecast period 2022 - 2028.

Who are the key vendors in the Global Myocardial Infarction (MI) Therapeutics Market?

Due to the presence of numerous established as well as new businesses in this sector, the market for myocardial infarction treatments is extremely fragmented and established. It is expected that new competitors will attempt to enter this market in the near future due to the rising incidence and prevalence of acute myocardial infarction and other cardiovascular disorders. 'Bayer HealthCare LLC (Germany)', 'Daiichi Sankyo, Inc. (Japan)', 'Eli Lilly and Company (US)', 'Janssen Biotech, Inc. (US)', 'Merck & Co. Inc. (US)', 'Novartis International AG (Switzerland)', 'Sanofi (France)', 'AstraZeneca (UK)', 'Pfizer (US)', 'Amgen, Inc (US)', 'GlaxoSmithKline PLC (UK)', 'Regeneron Pharmaceuticals Inc. (US)', 'Bristol-Myers Squibb Company (US)', 'Alnylam Pharmaceuticals Inc. (US)'

Myocardial Infarction (MI) Therapeutics Market Size

Myocardial Infarction (MI) Therapeutics Market Insights

Global Myocardial Infarction (MI) Therapeutics Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.73 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The main cause of myocardial infarction, often known as a heart attack, is coronary artery disease, which results in a decreased blood flow to the heart muscles. Myocardial infarction happens when an area of the heart loses oxygen because one of the coronary arteries is blocked. Typically, blockages form as a result of atherosclerotic plaque accumulation on artery walls. The septal, anterior, posterior, lateral, or inferior walls of the left ventricle of the heart are where myocardial infarctions are most often found. Thus, insufficient oxygen results in the death of cardiac tissue and a recognisable chest discomfort in humans, which causes myocardial infarction. Around 17.3 million people worldwide pass away from heart disease each year, with myocardial infarction being the main cause of death, according to the American Heart Association (AHA). This increases the requirement of treatments for myocardial infarction which leads to the growth of the myocardial infarction (MI) therapeutics market.

The growth of the market for myocardial infarction treatment is also due to the rising prevalence of cardiovascular disorders and the growing senior population. The increased frequency of obesity and chronic disorders like diabetes, hypertension, and chronic kidney disease are further reasons driving this market's expansion. Additionally, unhealthy lifestyle habits, excessive alcohol consumption, and drug use—including amphetamine and cocaine use—among the populace are significant risk factors for myocardial infarction. As a result, the market for myocardial infarction treatment and management products is expected to grow in the coming years. According to estimates, the global market for myocardial infarction treatments has the potential to be lucrative and to grow due to the rising popularity of efficient and secure treatment protocols. The market for myocardial infarction treatments may develop as a result of anticipated technology advancements that will create a plethora of chances for detecting specific blockages, monitoring cellular response, and determining hereditary predisposition.

US Myocardial Infarction (MI) Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.

FAQs

Due to the presence of numerous established as well as new businesses in this sector, the market for myocardial infarction treatments is extremely fragmented and established. It is expected that new competitors will attempt to enter this market in the near future due to the rising incidence and prevalence of acute myocardial infarction and other cardiovascular disorders. 'AstraZeneca Plc (UK) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Eli Lilly and Company (US) ', 'Amgen (US) ', 'Novartis AG (Switzerland) ', 'Idorsia Pharmaceuticals Ltd. (Switzerland) ', 'Faraday Pharmaceuticals (US) ', 'Immediate Therapeutics (US) ', 'Mitsubishi Chemical Group (Japan) ', 'Kancera (Sweden) ', 'Bayer AG (Germany) ', 'Recardio (US) ', 'Mesoblast Ltd. (Australia) ', 'Athera Biotechnologies AB (Sweden) ', 'Bristol Myers Squibb Co. (US) ', 'CeleCor Therapeutics (US) ', 'CHIESI Farmaceutici SpA (Italy) ', 'CSL Ltd. (Australia) ', 'Ever Supreme Bio Technology (Taiwan)'

The global myocardial infarction market is projected to increase as heart attacks become more common. Apart from this, the two main drivers anticipated to propel the growth of the global market for myocardial infarction therapies are the rising incidence of coronary artery disease and changes in lifestyle. Over the forecast period, rising blood pressure, obesity, and smoking rates, among other factors, are predicted to propel the global market for myocardial infarction treatments.

The delivery of medications and imaging probes using nanoparticle technology offers new approaches for the treatment of cardiovascular disease (CVD). With significant efforts being made to address therapy possibilities for myocardial infarction (MI), advancements in the production of nanoparticles, their design characteristics, and functional diversity have permitted its direct implementation in preclinical CVD research. It is possible to create nanocarrier systems with efficient cell-, tissue-, or disease-specific and targeted actions through the rational design of nanoparticles, resolving problems with low bioactive factor delivery efficiency, difficulty crossing biological barriers, ineffective bioimaging, and unfavorable off-target effects that would otherwise impede the advancement of cardiovascular medicine. In particular, the control of inflammation and fibrogenesis, the encouragement of angiogenesis, and accelerated tissue regeneration are driving efforts to create more effective therapeutic and diagnostic solutions for clinical issues faced by MI treatment.

Based on the region, the North American region currently dominates the global myocardial infarction (MI) therapeutics market. This is due to the rising prevalence of cardiovascular disorders and the growing senior population, that the market for myocardial infarction treatment is expanding admirably in this region. The increased frequency of obesity and chronic disorders like diabetes, hypertension, and chronic kidney disease are further reasons driving this market's expansion. Additionally, unhealthy lifestyle habits, excessive alcohol consumption, and drug use—including amphetamine and cocaine use—among the populace are significant risk factors for myocardial infarction. As a result, the market for myocardial infarction treatment and management products is expected to grow in the coming years. According to estimates, the global market for myocardial infarction treatments has the potential to be lucrative and to grow due to the rising popularity of efficient and secure treatment protocols. The market for myocardial infarction treatments may develop as a result of anticipated technology advancements that will create a plethora of chances for detecting specific blockages, monitoring cellular response, and determining hereditary predisposition.